Abstracts tagged "Outcome measures"

Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Leonieke van Mens¹, Arno van Kuijk², Dominique Baeten¹ and Laura C Coates³, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³LIRMM, University of Leeds, Leeds, United Kingdom
Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…
Abstract Number: 1238 • 2017 ACR/ARHP Annual Meeting
The Development of the Lupus Foundation of America—Rapid Evaluation of Activity in Lupus (LFA-REAL™) Patient-Reported Outcome (PRO) to Evaluate Lupus Disease Activity
Anca Askanase¹, Samantha Nguyen², Miya Okado², Nancy Leidy³ and Joan T. Merrill⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Evidera, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The LFA REALTM is designed as two complimentary disease activity measures in order to integrate clinician and patient input. The current report updates progress…
Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Laura C Coates¹, Proton Rahman², Eliofotisti Psaradellis³, Emmanouil Rampakakis³, Brendan Osborne⁴, Allen J Lehman⁵ and Francois Nantel⁴, ¹LIRMM, University of Leeds, Leeds, United Kingdom, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Janssen Inc., Toronto, ON, Canada
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
Abstract Number: 1293 • 2017 ACR/ARHP Annual Meeting
Indications for Cesarean Delivery in Systemic Lupus Erythematosus Pregnancies
Evelyne Vinet¹, Paul R. Fortin², Stéphanie Roberge³, Emmanuel Bujold⁴ and Nils Chaillet⁵, ¹Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ³Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada, ⁴Reproduction, mother and youth health, Centre Hospitalier de l'Université Laval (CHUL), Québec, QC, Canada, ⁵Département d’obstétrique et gynécologie et département de Médecine de famille et médecine d’urgence, Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Pregnant SLE women are at increased risk of cesarean delivery compared to pregnant women from the general population. Yet, to date, no one has…
Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Maria Laura Acosta Felquer¹, Musaab Elmamoun², Agnes Szentpetery^3,4, Phil Gallagher⁵, Oliver FitzGerald⁶ and Enrique R. Soriano⁷, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
Abstract Number: 2781 • 2017 ACR/ARHP Annual Meeting
Assessing RA Disease Activity with Promis Measures Using Smartphone Technology
Huifeng Yun¹, Shuo Yang², W. Benjamin Nowell³, Cooper Filby¹, Lang Chen¹ and Jeffrey R. Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health information technology has enabled efficient measurement of PROs using Computer Adaptive Testing (CAT) methods, which have been shown to minimize missing data and…
Abstract Number: 1384 • 2017 ACR/ARHP Annual Meeting
Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All over the Map!
Matthew Turk¹ and Janet E. Pope², ¹Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: Assessments of disease activity in rheumatoid arthritis (RA) determine the course of treatment. Physician global assessments of disease activity (MD globals) are important outcomes…
Abstract Number: 1511 • 2017 ACR/ARHP Annual Meeting
Real-Life Performance of the ASAS Health Index in Routine Care of Patients with Spondyloarthritis
Uta Kiltz, Thomas Wiatr, Xenofon Baraliakos, Kirill Fedorov and Jürgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: The ASAS Health Index (ASAS HI) have been developed to measure health and impairment in functioning in patients with spondyloarthritis (SpA). Its measurement properties…
Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Mahdi Gharaibeh¹, Yingxin Xu², Joseph Lee³, Madhura Chitnis² and David Collier⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Evidera, Bethesda, MD, ³videra, Bethesda, MD, ⁴Amgen, Inc, Terni, Italy
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…
Abstract Number: 1627 • 2017 ACR/ARHP Annual Meeting
Changes in Heart Rate Variability Reflect Changes in Clinical Status and Patient Reported Outcomes in Systemic Lupus Erythematosus: A Longitudinal Analysis
Aikaterini Thanou¹, Stavros Stavrakis², Justin Reynolds³, Stan Kamp¹, Paul Kamp¹, Judith A. James⁴ and Joan T. Merrill⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Ok, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: We have previously observed associations between systemic lupus erythematosus (SLE) disease activity and heart rate variability (HRV) between 2 time points (1). We aim…
Abstract Number: 1676 • 2017 ACR/ARHP Annual Meeting
Improving Sensitivity to Change of the Modified Rodnan Skin Score over Time
Annel M. Fernandez¹, Robert F. Spiera², Jackie Szymonifka² and Jessica K. Gordon², ¹Medicine- Rheumatology/ Research, Hospital For Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: The Modified Rodnan Skin Score (MRSS) assesses global dermal thickness through the examination of 17 body areas scored by clinical palpation using a 4…
Abstract Number: 1 • 2017 Pediatric Rheumatology Symposium
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 527 • 2016 ACR/ARHP Annual Meeting
The Summed Bilateral Elbow Extension Angle in Rheumatoid Arthritis Correlates with the DAS28-CRP(4) and May be an Independent Marker of Bad Prognosis
John P. Case¹, Congbin Wang² and Heidi Tucker³, ¹Internal Medicine/Rheumatology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ²Internal medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, ³Rush Medical College, Chicago, IL
Background/Purpose: The elbow is an easily-examined joint and an important determinant of morbidity in rheumatoid arthritis (RA). In active RA the measured elbow extension angle,…
Abstract Number: 3095 • 2016 ACR/ARHP Annual Meeting
What Should be the Primary Target of ‘Treat to Target’ in Psa?
Laura C. Coates^1,2, Paul Emery³, Philip G. Conaghan¹ and Philip S. Helliwell¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In 2013, Treat to Target (T2T) in SpA Recommendations by expert consensus stated that the target of treatment should be remission or inactive disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].